Market Research Report Juvenile Macular Degeneration Pipeline Review 2017

Juvenile Macular Degeneration (Stargardt Disease) -
Pipeline Review and Research Report 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report,
titled “Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1
2017” to its report offerings. The report provides comprehensive information on the
therapeutics under development for Juvenile Macular Degeneration
(Ophthalmology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Request Free Sample Report:
http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049078
Summary
 Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline
guide Juvenile Macular Degeneration Pipeline Review, H1 2017, provides an
overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline
landscape.
 Juvenile macular degeneration is a series of inherited eye disorders that affects
children and young adults. The most common form of juvenile macular
degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal
recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark,
empty spots in the center of vision and difficulty reading or performing detail
work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking
and hypertension.